Welcome to our dedicated page for BridgeBio Oncology Therapeutics news (Ticker: BBOT), a resource for investors and traders seeking the latest updates and insights on BridgeBio Oncology Therapeutics stock.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company listed on Nasdaq and based in South San Francisco, California. The company reports that it is focused on RAS-pathway malignancies and is advancing a pipeline of orally bioavailable small molecule therapeutics targeting RAS and PI3Kα. The BBOT news flow reflects both scientific developments and corporate milestones related to this precision oncology strategy.
News updates from BBOT commonly cover clinical data readouts, preclinical findings, and trial progress for its three main programs: BBO-8520, a direct KRASG12C ON/OFF inhibitor; BBO-11818, a panKRAS inhibitor targeting mutant KRAS; and BBO-10203, a RAS:PI3Kα breaker designed to inhibit the physical interaction between RAS and PI3Kα. Releases have detailed early safety and antitumor activity in Phase 1 trials such as ONKORAS-101, KONQUER-101, and BREAKER-101, as well as mechanistic and efficacy data from preclinical models.
Investors and observers can also find corporate and capital markets announcements in BBOT’s news, including its debut as a publicly traded company on the Nasdaq Global Market following a business combination with Helix Acquisition Corp. II, participation in investor healthcare conferences, and updates on its financial position and operating runway as described by the company. Additional items include disclosures about inducement equity grants made under the company’s 2025 Inducement Plan in connection with new hires.
This news page aggregates BBOT’s press releases so readers can follow developments in its RAS and PI3Kα-focused pipeline, including updates on early clinical outcomes, preclinical presentations at scientific meetings, and corporate communications related to its status as a clinical-stage biopharmaceutical company.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said members of its leadership team will participate in two investor healthcare conferences in Feb–Mar 2026.
Presentations: Oppenheimer on Feb 25, 2026 at 10:40 a.m. ET and Leerink on Mar 10, 2026 at 10:00 a.m. ET. Live webcasts will be available on BBOT's Events page and replays will be accessible for at least 90 days.
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced inducement stock-option grants awarded Feb 10, 2026, to two employees hired in January 2026 under its 2025 Inducement Plan.
The awards total 65,350 non-qualified stock options at an exercise price of $10.84 per share, vesting 25% after one year then monthly over 36 months. Grants were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced on January 13, 2026 that it awarded an inducement grant on January 10, 2026 under its 2025 Inducement Plan to an individual hired in December 2025.
The grant comprises non-qualified stock options to purchase 129,090 shares of common stock at an exercise price of $13.19 per share (the Nasdaq closing price on the grant date). The options vest 25% on the first anniversary of the employee’s start date and then in 36 equal monthly installments, subject to continued service. The 2025 Inducement Plan was adopted by the board in October 2025, and the awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported preliminary Phase 1 safety and antitumor data across three oral RAS/PI3Kα programs: BBO-8520, BBO-11818, and BBO-10203. Key highlights include a 65% ORR (11/17) and 66% 6-month PFS in KRASG12C NSCLC with BBO-8520 monotherapy (data cutoff Nov 15, 2025), durable responses in combination with pembrolizumab, and responses in KRASG12C/STK11 and/or KEAP1 co-mutants. BBO-11818 showed a confirmed PR in pretreated PDAC with a 56% tumor reduction at higher dose levels (data cutoff Dec 10, 2025). BBO-10203 selected a 500 mg QD expansion dose, reported no hyperglycemia, and is advancing combination cohorts. Additional combination and expansion data expected H2 2026.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said its leadership will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 5:15 p.m. PT. A live webcast will be available on the company’s Events page and a replay will remain accessible for at least 90 days after the presentation.
This provides investors a scheduled opportunity for management commentary on clinical programs and strategy.
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced an inducement grant awarded December 10, 2025 under BBOT’s 2025 Inducement Plan for an individual hired in November 2025.
The award comprises non-qualified stock options to purchase 53,060 shares at an exercise price of $12.88 per share (the Nasdaq closing price on the grant date). Options vest 25% after one year and the remainder in 36 equal monthly installments, subject to continued service.
The 2025 Inducement Plan was adopted by the board in October 2025 and the compensation committee (all independent directors) approved the Awards as a material inducement under Nasdaq Listing Rule 5635(c)(4).
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced late-breaking preclinical data on BBO-10203 at SABCS on Dec 10, 2025. Data show BBO-10203 is a first-in-class covalent RAS:PI3Kα breaker that binds PI3Kα at Cys242, blocks RAS-driven PI3Kα-AKT signaling, and produces dose- and time-dependent pAKT inhibition after oral dosing without inducing hyperglycemia in glucose tolerance testing.
BBO-10203 demonstrated robust anti-tumor activity as monotherapy and combined with fulvestrant, ribociclib, trastuzumab or chemotherapy in preclinical breast cancer models. A Phase 1 trial (BREAKER-101; NCT06625775) is enrolling with initial Phase 1 data expected in first half of 2026.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said members of its leadership team will present at two investor healthcare conferences in early December 2025.
Presentation schedule: Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 PM ET, and Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:35 AM ET. Live webcasts will be available on the company's Events page, with replays accessible for at least 90 days after each event.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported Q3 2025 results and corporate updates on Nov 12, 2025. The company closed a SPAC business combination in August and began trading as BBOT. As of Sept 30, 2025, BBOT held $468.3 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028. BBOT advanced three internally discovered Phase 1 programs (BBO-8520, BBO-10203, BBO-11818) and expects initial clinical data readouts across the portfolio in 2026. BBO-8520 has FDA Fast Track designation for previously treated KRAS G12C metastatic NSCLC. Q3 operating metrics included R&D expenses of $35.1M, G&A expenses of $14.1M, and a net loss of $44.8M.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced that its leadership team will present at the Jefferies Global Healthcare Conference on Monday, November 17, 2025 at 2:30 p.m. GMT. A live webcast will be available on the company’s Events page at https://investors.bbotx.com/news-events/events. A replay of the webcast will be accessible for at least 90 days after the event.